Tandem Diabetes Care's total inventories for the quarter that ended in Mar. 2026 was $126 Mil. Tandem Diabetes Care's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was $128 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Tandem Diabetes Care's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was $-4.12.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Tandem Diabetes Care's Days Inventory for the
three
months ended in Mar. 2026 was 105.42.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Tandem Diabetes Care's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.87.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Tandem Diabetes Care's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.52.
Tandem Diabetes Care (LTS:0M0F) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Tandem Diabetes Care's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Tandem Diabetes Care's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Tandem Diabetes Care Total Inventories Related Terms
Tandem Diabetes Care Total Inventories Historical Data
* Premium members only.
The historical data trend for Tandem Diabetes Care's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Tandem Diabetes Care (LTS:0M0F) has a Total Inventories of $126 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Tandem Diabetes Care and its competitors.
Is Tandem Diabetes Care's Total Inventories too high?
Tandem Diabetes Care's current Total Inventories is $126 Mil. Overall, Tandem Diabetes Care has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Total Inventories compare to ATEC and BFLY?
Tandem Diabetes Care's Total Inventories of $126 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current Total Inventories is $126 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $29.23, compared to a current price of $15.87 — trading 45.7% below its estimated fair value. The current Total Inventories is $126 Mil. Tandem Diabetes Care's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current Total Inventories is $126 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of $15.87 is trading 45.7% below its estimated GF Value™ of $29.23.
GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.
Key valuation signals for LTS:0M0F:
Total Inventories: $126 Mil
GF Value™: $29.23 vs. price of $15.87 (45.7% below fair value)
No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
67GF Score
Get the complete analysis for LTS:0M0F
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M0F has been successfully added to your 
